^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    lenrispodun (ITI-214)

    i
    Other names: ITI-214, IC200214, ITI 214, IC-200214, ITI214, ITI-002
    Associations

    News

    Trials
    Company:
    J&J
    Drug class:
    PDE1 inhibitor
    Associations

    News

    Trials
    over1year
    Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease (clinicaltrials.gov)
    P2, N=132, Recruiting, Intra-Cellular Therapies, Inc. | Trial completion date: Feb 2025 --> Oct 2025 | Trial primary completion date: Feb 2025 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    COMT (Catechol-O-Methyltransferase)
    |
    lenrispodun (ITI-214)
    over2years
    Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease (clinicaltrials.gov)
    P2, N=132, Recruiting, Intra-Cellular Therapies, Inc. | Trial completion date: Nov 2024 --> Feb 2025 | Trial primary completion date: Nov 2024 --> Feb 2025
    Trial completion date • Trial primary completion date
    |
    COMT (Catechol-O-Methyltransferase)
    |
    lenrispodun (ITI-214)
    almost4years
    ITI-214, a potent and selective PDE1 inhibitor, inhibits tumor growth when combined with a checkpoint inhibitor in a mouse model of breast cancer (AACR 2022)
    In conclusion, this study demonstrates a synergistic ability of ITI-214 and anti-PD-1 to alter the tumor microenvironment and control tumor growth in mice. Translating these findings to the clinic suggests that ITI-214 may provide a means to expand the utility of immune checkpoint inhibitors to treatment-refractory tumors.
    Preclinical • Checkpoint inhibition
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CCL2 (Chemokine (C-C motif) ligand 2)
    |
    lenrispodun (ITI-214)
    almost5years
    [VIRTUAL] Effects of ITI-214, a potent and selective phosphodiesterase type 1 inhibitor, on tumor myeloid cellular composition, tumor volume and survival in mouse models of colorectal cancer when combined with an anti-PD-1 checkpoint inhibitor (AACR 2021)
    Together, these studies demonstrate a synergistic ability of ITI-214 and anti-PD-1 to alter the tumor environment and control tumor growth. Translating these findings to humans suggests that ITI-214 may provide a means to expand the utility of immune checkpoint inhibitors in immunogenic tumors.
    Preclinical • Checkpoint inhibition
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • CCL2 (Chemokine (C-C motif) ligand 2)
    |
    lenrispodun (ITI-214)